vs
Side-by-side financial comparison of James River Group Holdings, Inc. (JRVR) and Vericel Corp (VCEL). Click either name above to swap in a different company.
James River Group Holdings, Inc. is the larger business by last-quarter revenue ($151.4M vs $92.9M, roughly 1.6× Vericel Corp). On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -12.1%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -10.3%).
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
JRVR vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.4M | $92.9M |
| Net Profit | — | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | — | 25.0% |
| Revenue YoY | -12.1% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | — | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $151.4M | — | ||
| Q4 25 | $167.7M | $92.9M | ||
| Q3 25 | $172.7M | $67.5M | ||
| Q2 25 | $174.8M | $63.2M | ||
| Q1 25 | $172.3M | $52.6M | ||
| Q4 24 | $126.7M | $75.4M | ||
| Q3 24 | $191.5M | $57.9M | ||
| Q2 24 | $188.3M | $52.7M |
| Q1 26 | — | — | ||
| Q4 25 | $32.1M | $23.2M | ||
| Q3 25 | $1.0M | $5.1M | ||
| Q2 25 | $4.8M | $-553.0K | ||
| Q1 25 | $9.6M | $-11.2M | ||
| Q4 24 | $-64.8M | $19.8M | ||
| Q3 24 | $-39.4M | $-901.0K | ||
| Q2 24 | $7.6M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 14.6% | 24.1% | ||
| Q3 25 | 1.5% | 5.1% | ||
| Q2 25 | 4.2% | -3.2% | ||
| Q1 25 | 9.3% | -24.3% | ||
| Q4 24 | -57.0% | 24.5% | ||
| Q3 24 | -27.1% | -4.3% | ||
| Q2 24 | 10.7% | -11.5% |
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | 25.0% | ||
| Q3 25 | 0.6% | 7.5% | ||
| Q2 25 | 2.7% | -0.9% | ||
| Q1 25 | 5.6% | -21.4% | ||
| Q4 24 | -51.1% | 26.3% | ||
| Q3 24 | -20.6% | -1.6% | ||
| Q2 24 | 4.0% | -8.9% |
| Q1 26 | — | — | ||
| Q4 25 | $0.59 | $0.46 | ||
| Q3 25 | $-0.02 | $0.10 | ||
| Q2 25 | $0.06 | $-0.01 | ||
| Q1 25 | $0.16 | $-0.23 | ||
| Q4 24 | $-2.44 | $0.40 | ||
| Q3 24 | $-1.10 | $-0.02 | ||
| Q2 24 | $0.13 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $228.2M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $518.4M | $354.6M |
| Total Assets | $4.8B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $228.2M | — | ||
| Q4 25 | $260.9M | $137.5M | ||
| Q3 25 | $238.8M | $135.4M | ||
| Q2 25 | $220.0M | $116.9M | ||
| Q1 25 | $279.4M | $112.9M | ||
| Q4 24 | $362.3M | $116.2M | ||
| Q3 24 | $359.8M | $101.7M | ||
| Q2 24 | $672.5M | $102.5M |
| Q1 26 | $518.4M | — | ||
| Q4 25 | $538.2M | $354.6M | ||
| Q3 25 | $503.6M | $321.9M | ||
| Q2 25 | $492.6M | $306.8M | ||
| Q1 25 | $484.5M | $295.5M | ||
| Q4 24 | $460.9M | $292.0M | ||
| Q3 24 | $530.3M | $257.5M | ||
| Q2 24 | $541.8M | $243.0M |
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.9B | $488.0M | ||
| Q3 25 | $5.0B | $453.3M | ||
| Q2 25 | $5.0B | $435.6M | ||
| Q1 25 | $4.9B | $424.6M | ||
| Q4 24 | $5.0B | $432.7M | ||
| Q3 24 | $5.0B | $390.4M | ||
| Q2 24 | $4.7B | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.8M | $15.0M | ||
| Q3 25 | $34.3M | $22.1M | ||
| Q2 25 | $25.2M | $8.2M | ||
| Q1 25 | $-51.5M | $6.6M | ||
| Q4 24 | $-247.1M | $22.2M | ||
| Q3 24 | $-269.9M | $10.2M | ||
| Q2 24 | $-8.7M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-23.6M | $12.8M | ||
| Q3 25 | $33.7M | $19.5M | ||
| Q2 25 | $24.7M | $81.0K | ||
| Q1 25 | $-52.7M | $-7.6M | ||
| Q4 24 | $-252.0M | $8.5M | ||
| Q3 24 | $-270.8M | $-9.2M | ||
| Q2 24 | $-9.3M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | -14.1% | 13.8% | ||
| Q3 25 | 19.5% | 28.8% | ||
| Q2 25 | 14.1% | 0.1% | ||
| Q1 25 | -30.6% | -14.5% | ||
| Q4 24 | -198.9% | 11.2% | ||
| Q3 24 | -141.4% | -15.9% | ||
| Q2 24 | -4.9% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.9% | 2.4% | ||
| Q3 25 | 0.4% | 3.9% | ||
| Q2 25 | 0.3% | 12.9% | ||
| Q1 25 | 0.7% | 27.0% | ||
| Q4 24 | 3.9% | 18.3% | ||
| Q3 24 | 0.4% | 33.5% | ||
| Q2 24 | 0.3% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | -0.59× | 0.65× | ||
| Q3 25 | 33.61× | 4.35× | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | -5.38× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JRVR
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
